OncLive® On Air

S18 Ep35: The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Antibody-drug conjugates (ADCs) have transformed the treatment landscape for metastatic triple-negative breast cancer, offering new first-line options for patients with limited alternatives. Clinical data for agents like sacituzumab govitecan and datopotamab deruxtecan demonstrate significant improvements in progressio...

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

S18 Ep32: Non–Small Cell Lung Cancer 2026 UPDATE

Early-stage and locally advanced non-small cell lung cancer (NSCLC) management centers on the 9th edition TNM staging system, which introduces critical updates to N2 and M1C categories. Clinical practice requires mandatory biomarker testing for EGFR, ALK, RET, and PD-L1 to guide therapeutic selection. For resectable ca...

S18 Ep31: FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

S18 Ep31: Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

S18 Ep30: FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

S18 Ep28: Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

S18 Ep27: Key Considerations for Health Equity and Patient-Centered Care in TNBC

S18 Ep26: FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

S18 Ep25: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

S18 Ep24: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

S18 Ep23: From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

S18 Ep22: FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

S18 Ep21: Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

S18 Ep20: Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

S18 Ep19: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

S18 Ep18: Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

S18 Ep17: Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

S18 Ep16: FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD